HUP0203706A2 - Alfa-interferon vizes oldat kiszerelése - Google Patents

Alfa-interferon vizes oldat kiszerelése

Info

Publication number
HUP0203706A2
HUP0203706A2 HU0203706A HUP0203706A HUP0203706A2 HU P0203706 A2 HUP0203706 A2 HU P0203706A2 HU 0203706 A HU0203706 A HU 0203706A HU P0203706 A HUP0203706 A HU P0203706A HU P0203706 A2 HUP0203706 A2 HU P0203706A2
Authority
HU
Hungary
Prior art keywords
interferon
aqueous solution
solution formulation
alpha
long period
Prior art date
Application number
HU0203706A
Other languages
English (en)
Inventor
Kyuboem Han
Young Cheol Kang
Sang-Heon Lee
Original Assignee
Lg Chem Investment, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chem Investment, Ltd. filed Critical Lg Chem Investment, Ltd.
Publication of HUP0203706A2 publication Critical patent/HUP0203706A2/hu
Publication of HUP0203706A3 publication Critical patent/HUP0203706A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

A találmány olyan vizes oldatkiszerelésre vonatkozik, amely hosszúidőtartamon át képes megőrizni az a-interferon biológiai aktivitásátés fizikokémiai tulajdonságait. Pontosabban a találmány a-interferonolyan vizes oldatkiszerelésére vonatkozik, amely tartalmaz a-interferont; valamely stabilizálószert; valamely ozmotikus nyomástszabályozó szert; antimikrobiális tartósítószert, amely fenol, m-krezol vagy ezek valamely keveréke lehet; és egy pufferrendszert. Atalálmány szerinti vizes oldatkiszerelésnek számos előnye van, mivelez hosszú időtartamon át megőrzi az a-interferon aktivitását,eltünteti a lehetséges károkozást az emberi testre a tartósítószerekmennyiségének minimalizálásával, és nagyon stabil. Ó
HU0203706A 1999-11-19 2000-11-17 An aqueous solution formulation of alpha-interferon HUP0203706A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-1999-0051481A KR100399156B1 (ko) 1999-11-19 1999-11-19 α-인터페론의 용액제형
PCT/KR2000/001322 WO2001035987A1 (en) 1999-11-19 2000-11-17 An aqueous solution formulation of alpha-interferon

Publications (2)

Publication Number Publication Date
HUP0203706A2 true HUP0203706A2 (hu) 2003-03-28
HUP0203706A3 HUP0203706A3 (en) 2004-12-28

Family

ID=36782398

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203706A HUP0203706A3 (en) 1999-11-19 2000-11-17 An aqueous solution formulation of alpha-interferon

Country Status (23)

Country Link
EP (1) EP1231933B1 (hu)
JP (1) JP3893286B2 (hu)
KR (1) KR100399156B1 (hu)
CN (1) CN1203892C (hu)
AR (1) AR026507A1 (hu)
AT (1) ATE333891T1 (hu)
AU (1) AU777994B2 (hu)
BR (1) BR0015699A (hu)
CA (1) CA2391889A1 (hu)
CY (1) CY1105449T1 (hu)
DE (1) DE60029614T2 (hu)
DK (1) DK1231933T3 (hu)
ES (1) ES2267584T3 (hu)
HU (1) HUP0203706A3 (hu)
MX (1) MXPA02005105A (hu)
PE (1) PE20010903A1 (hu)
PL (1) PL356406A1 (hu)
PT (1) PT1231933E (hu)
RU (1) RU2232595C2 (hu)
TR (1) TR200201310T2 (hu)
TW (1) TWI223596B (hu)
WO (1) WO2001035987A1 (hu)
ZA (1) ZA200204096B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
RU2447897C2 (ru) * 2009-03-26 2012-04-20 Сергей Юрьевич Родионов Цитокинсодержащая композиция для лечения вирусных заболеваний
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
CN105055306B (zh) 2010-05-28 2019-10-01 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
SG11201502930XA (en) 2012-10-26 2015-05-28 Lupin Ltd Stable pharmaceutical composition of peginterferon alpha-2b
CN104888196B (zh) * 2015-06-25 2018-07-06 北京三元基因药业股份有限公司 一种稳定的干扰素α多剂量笔注射液
CN105456186A (zh) * 2015-12-24 2016-04-06 杭州嘉伟生物制品有限公司 一种生理平衡液的制备方法
CN114259556B (zh) * 2021-12-24 2024-05-31 科兴生物制药股份有限公司 人干扰素α2b喷雾剂及其制备方法
CN114053397B (zh) * 2022-01-17 2022-12-20 北京三元基因药业股份有限公司 一种稳定的干扰素多剂量注射液及其制备方法
CN115068592A (zh) * 2022-06-27 2022-09-20 长春生物制品研究所有限责任公司 开封后常温稳定的重组人干扰素α1b滴眼液及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤

Also Published As

Publication number Publication date
MXPA02005105A (es) 2002-11-07
TWI223596B (en) 2004-11-11
WO2001035987A1 (en) 2001-05-25
ZA200204096B (en) 2003-02-26
DE60029614T2 (de) 2007-07-12
DE60029614D1 (de) 2006-09-07
KR100399156B1 (ko) 2003-09-26
EP1231933A1 (en) 2002-08-21
TR200201310T2 (tr) 2002-09-23
CY1105449T1 (el) 2010-04-28
PL356406A1 (en) 2004-06-28
JP3893286B2 (ja) 2007-03-14
AU1421601A (en) 2001-05-30
RU2232595C2 (ru) 2004-07-20
ATE333891T1 (de) 2006-08-15
PT1231933E (pt) 2006-10-31
CN1203892C (zh) 2005-06-01
HUP0203706A3 (en) 2004-12-28
DK1231933T3 (da) 2006-10-30
AR026507A1 (es) 2003-02-12
CN1391478A (zh) 2003-01-15
AU777994B2 (en) 2004-11-11
ES2267584T3 (es) 2007-03-16
JP2003514027A (ja) 2003-04-15
BR0015699A (pt) 2002-07-23
EP1231933B1 (en) 2006-07-26
PE20010903A1 (es) 2001-08-31
CA2391889A1 (en) 2001-05-25
RU2002116364A (ru) 2004-01-20
KR20010047312A (ko) 2001-06-15

Similar Documents

Publication Publication Date Title
HUP0203706A2 (hu) Alfa-interferon vizes oldat kiszerelése
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2005082399A3 (en) Treatment of bacterial infections
ZA200307161B (en) Medical aerosol formulations
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
WO2004103315A3 (en) Treatment of ophthalmic infections using antimicrobial peptides
UA94032C2 (ru) Жидкая стабализированная композиция интерферона без hsa
ATE531419T1 (de) Vorrichtung zur verabreichung von therapeutischen mitteln
EP1019084A4 (en) NEW ANTIMICROBIAL POLYPEPTIDES AND METHOD FOR THEIR USE.
EP1236465A3 (en) Use of legume products for the treatment of external aggressions
AU1848901A (en) A stable aqua formulation of interferon, the preparation method and the uses thereof
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2002072621A3 (en) Cyclohexapeptide having antimicrobial activity
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
ATE221778T1 (de) Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung
HK1061209A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
BR0108792A (pt) Composto de polipeptìdeo, processo para sua preparação, composição farmacêutica contendo o mesmo, seu uso, método, embalagem comercial e artigo de manufatura
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
CO5251413A1 (es) Uso nuevo
WO2000041526A3 (en) Use of s-triazines for treating apicomplexan parasitic infections
WO2002002087A3 (de) Anthelmintika zur verhinderung von parasitären infektionen bei menschen und tieren ii
WO2002069984A3 (de) Verwendung von hyaluronsäure-uroniden zur behandlung von entzündlichen vorgängen
WO2004108744A3 (en) Azalides and azaketolides having antimicrobial activity

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees